title: Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients.
abstract: The influence of steroids on the antibody response to a MF59-adjuvanted influenza vaccine in elderly COPD patients has not been studied previously. In the influenza season 2001/02 (October-February) elderly COPD patients were recruited at 14 doctor's offices and our 250-bed hospital. Patients were stratified into three groups according to current treatment regimen: (a) > 10 mg of prednisolone/day (SS); (b) inhaled steroids (IS); (c) no steroid treatment (control group, CG). All patients were vaccinated with the MF59-adjuvanted influenza vaccine. Antibodies against the influenza strains A/H1N1, A/H3N2, and B were measured at baseline, 4 and 24 weeks after vaccination by hemagglutination inhibition (HI) assay. One-hundred and sixty-two patients completed the study (CG n = 42; IS n = 87; SS n = 33). Mean age was 71.3 years (range 60-89). Twenty-one percent of all patients reported local reactions; no serious adverse events were observed. Four weeks after vaccination, mean geometric HI titres (GMT) for A/H1N1, A/H3N and B increased significantly in all groups (p < or = 0.05). After 24 weeks, GMTs to A/H1N1 and A/H3N2 returned to baseline, while GMTs to type B remained significantly higher than baseline in all groups. Significant differences between the groups as regards GMTs, seroconversion (56-89%) or seroprotection rates (64-93%) were not observed. Systemic steroids did not influence the antibody response towards the MF59-adjuvanted influenza vaccine. We found that the strains included in the vaccine showed varying long-term immunogenicity.
authors.affiliation: Department of Chest and Infectious Diseases, Heckeshorn, Helios Kliniken Emil von Behring, Berlin, Germany. ADeroux@aol.com
authors.forename: A
authors.initials: A
authors.lastname: de Roux
authors.forename: A
authors.initials: A
authors.lastname: Marx
authors.forename: O
authors.initials: O
authors.lastname: Burkhardt
authors.forename: B
authors.initials: B
authors.lastname: Schweiger
authors.forename: A
authors.initials: A
authors.lastname: Borkowski
authors.forename: A
authors.initials: A
authors.lastname: Banzhoff
authors.forename: M W R
authors.initials: MW
authors.lastname: Pletz
authors.forename: H
authors.initials: H
authors.lastname: Lode
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000305:Adrenal Cortex Hormones / Q000494:pharmacology*; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007252:Influenza Vaccines / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011136:Polysorbates / Q000494:pharmacology*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000276:immunology; D013185:Squalene / Q000494:pharmacology*; D014611:Vaccination
chemical_list: D000276:Adjuvants, Immunologic; D000305:Adrenal Cortex Hormones; D000914:Antibodies, Viral; D007252:Influenza Vaccines; C089950:MF59 oil emulsion; D011136:Polysorbates; D013185:Squalene